Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6100570 | Journal of Crohn's and Colitis | 2012 | 4 Pages |
Abstract
In recent years, the use of antibodies against tumor necrosis factor α (TNFα) has expanded in rheumatology, gastroenterology, and dermatology. In addition to the more common side effects such as infections and hypersensitivity reactions, elevations of liver enzymes have been reported during anti-TNFα therapy, although severe liver failure has been extremely uncommon. This report describes a patient with severe liver failure after induction therapy with the TNFα antibody infliximab (Remicade®). A 46-year old female patient received two infusions of infliximab at a dose of 400 mg on weeks 0 and 8 for steroid-dependent ulcerative colitis. Eight weeks after the second infusion, she suffered acute liver failure with necrosis, requiring liver transplantation.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Urpo Kinnunen, Martti Färkkilä, Heikki Mäkisalo,